Relief Therapeutics Holding Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Michelle Lock

Chief executive officer

CHF92.5k

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	1.2yrs
Board average tenure	2.9yrs

Recent management updates

Recent updates

CEO

Michelle Lock (55 yo)

less than a year

Tenure

CHF92,473

Compensation

Ms. Michelle Lock serves as the Interim Chief Executive Officer and Director since November 22, 2023 at Relief Therapeutics Holding AG and served as its Independent Director from January 28, 2022. She serv...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Michelle Lock	Interim CEO & Director	less than a year	CHF92.47k	no data
Jeremy Meinen	CFO & Treasurer	1.2yrs	no data	0.0028% CHF 591.3
Paolo Galfetti	Chief Operating Officer	1.3yrs	CHF150.00k	0.62% CHF 131.0k

1.2yrs

Average Tenure

55yo

Average Age

Experienced Management: V6M1's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Michelle Lock	Interim CEO & Director	2.1yrs	CHF92.47k	no data
Raghuram Selvaraju	Chairman of the Board	7.8yrs	CHF500.00k	no data
Thomas Plitz	Vice-Chairman	3.2yrs	CHF150.00k	0.010% CHF 2.1k
Patrice Jean	Independent Director	2.7yrs	CHF150.00k	0.0028% CHF 587.1

2.9yrs

Average Tenure

53.5yo

Average Age

Experienced Board: V6M1's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.

Relief Therapeutics Holding Management

Management criteria checks 1/4

Key information

Recent management updates

Relief Therapeutics Holding Sa Announces CEO Changes

Relief Therapeutics Holding AG, Annual General Meeting, Jun 20, 2023

Relief Therapeutics Holding AG Appoints Jeremy Meinen as Chief Financial Officer

RELIEF THERAPEUTICS Holding SA Promotes Paolo Galfetti to Chief Operating Officer

Relief Therapeutics Holding SA Appoints David McCullough as Head of U.S. Market Access, Effective August 22, 2022

Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine

Recent updates

Relief Therapeutics Holding SA announced that it expects to receive CHF 50 million in funding from Global Emerging Markets and another investor

Relief Therapeutics Holding Sa Announces CEO Changes

Relief Therapeutics Holding AG announced that it expects to receive CHF 5 million in funding

Relief Therapeutics Holding AG, Annual General Meeting, Jun 20, 2023

Relief Therapeutics Announces Enrollment of First Three Patients in Proof-Of-Concept Clinical Trial of Rlf-Td011 for the Treatment of Epidermolysis Bullosa

RELIEF THERAPEUTICS Holding SA Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom

Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of Olpruva™ for Patients with Urea Cycle Disorders

Relief Therapeutics Holding AG (SWX:RLF) acquired ZYESAMI of NRx Pharmaceuticals, Inc.

Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announces Close of Definitive Settlement Agreements

Relief Therapeutics Holding AG Appoints Jeremy Meinen as Chief Financial Officer

Relief Therapeutics Holding AG Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)

RELIEF THERAPEUTICS Holding SA Promotes Paolo Galfetti to Chief Operating Officer

Relief Therapeutics Holding SA Announces U.S. Launch of PKU GOLIKE

Relief Therapeutics Holding AG Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa At Ann & Robert H. Lurie Children's Hospital of Chicago

Relief Therapeutics Holding AG has filed an IPO.

Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announce Tentative Settlement of Pending Litigation

Relief Therapeutics Holding SA Appoints David McCullough as Head of U.S. Market Access, Effective August 22, 2022

RELIEF THERAPEUTICS Holding SA and Acer Therapeutics Inc. Announce That the European Commission Has Granted Orphan Drug Designation for Acer-001 in Maple Syrup Urine Disease

Relief Therapeutics Holding Ag Announces U.S. Food and Drug Administration Accepts for Review Acer’s Resubmitted New Drug Application

Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs

Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine

Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application for ACER-001

Relief Therapeutics Expands U.S. Commercial Team

Acer Therapeutics Inc. and Relief Therapeutics Holding AG Announce Presentation of Acer-001 Data At the Genetic Metabolic Dieticians International Conference

Relief Therapeutics Holding AG, Annual General Meeting, May 31, 2022

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age